The Commodity Futures Trading Commission and the Securities and Exchange Commission have launched a joint public comment process on derivatives product definitions under Title VII of the Dodd-Frank Act. The 60-day comment window opens after publication in the Federal Register, and the outcome could determine whether cryptocurrency perpetual futures land under futures-style rules or stricter swap-style requirements.
Why perpetuals are at the center
Perpetual futures act like futures in trading behavior — no expiration, continuous funding — but critics argue their economic design overlaps with swap exposure. That ambiguity is now under a legal microscope. The CME is challenging the CFTC's approval path for certain retail perpetual contracts, arguing the agency overstepped. The definitions process aims to clear up exactly what counts as a future versus a swap under Title VII — a distinction that carries very different clearing and compliance obligations.
What Chairman Selig said
CFTC Chairman Michael Selig said the comment request offers a chance to address ambiguities within Title VII that have limited competition and innovation. “This is an opportunity to hear from market participants on how to resolve those ambiguities,” he said. The comment period won't produce an immediate rule change, and the CME litigation remains unresolved.
What could change
If perpetuals end up classified as futures, more regulated venues could compete for crypto derivatives flow. If they're treated as swaps, exchanges would face heavier compliance and centralized clearing mandates, potentially narrowing the field to larger, better-capitalized players. The CFTC and SEC are both collecting feedback, so the final definition could also carve out a middle ground — or kick the question back to Congress.
The next signal
The real action happens over the next 60 days as exchanges, trading firms, and incumbents file their comments. Their arguments — especially around how perpetuals behave in practice versus how Dodd-Frank categorizes them — will shape the agencies' next move. Meanwhile, the CME case continues to wind through the courts, meaning regulatory clarity could arrive in pieces rather than all at once.
